Sanders takes aim at US drug prices of Novo's Ozempic and Wegovy [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Health, Education, Labor, and Pensions (HELP) is investigating the “outrageously high” US prices of the blockbuster diabetes and obesity drugs. In a 24 April letter addressed to Novo Nordisk CEO Lars Fruergaard Jørgensen, Sanders, who serves as the HELP Committee chair, has requested answers from the multinational pharma by 8 May. The letter said the committee is investigating future reductions of the list and net prices of both Ozempic and Wegovy, R&D spending, cost and volume of goods sold, and prices paid by government payers. Additionally, Sanders requested that Novo Nordisk explain the price discrepancy between Wegovy and Ozempic given that they are different versions of the same drug, semaglutide, sold under two brand names. Sanders had previously put forth a proposal to cap prices on federally-funded drugs in 2023. As per the letter, the costs of Ozempic and Wegovy—which are estimated to be profitably manufactured for less than $5 per month—are 15 times higher in the US c
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Why Amgen Stock Zoomed Nearly 12% Higher Today [Yahoo! Finance]Yahoo! Finance
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance Canada]Yahoo! Finance Canada
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/2/24 - Form 6-K
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- NVO's page on the SEC website